| Multiplexed imaging for diagnosis and therapy K Heinzmann, LM Carter, JS Lewis, EO Aboagye Nature Biomedical Engineering 1 (9), 697, 2017 | 159 | 2017 |
| AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity TA Yap, MI Walton, KM Grimshaw, RH te Poele, PD Eve, MR Valenti, ... Clinical Cancer Research 18 (14), 3912-3923, 2012 | 98 | 2012 |
| Preclinical Applications of 3'-Deoxy-3'-[18F] Fluorothymidine in Oncology-A Systematic Review S Schelhaas, K Heinzmann, VR Bollineni, GM Kramer, Y Liu, JC Waterton, ... Theranostics 7 (1), 40, 2017 | 40 | 2017 |
| Variability of proliferation and diffusion in different lung cancer models as measured by 3′-deoxy-3′-18F-fluorothymidine PET and diffusion-weighted MR imaging S Schelhaas, L Wachsmuth, T Viel, DJ Honess, K Heinzmann, DM Smith, ... Journal of Nuclear Medicine 55 (6), 983-988, 2014 | 29 | 2014 |
| Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[18F] Fluorothymidine in Preclinical Models of Lung Cancer S Schelhaas, A Held, L Wachsmuth, S Hermann, DJ Honess, ... Cancer Research 76 (24), 7096-7105, 2016 | 19 | 2016 |
| The relationship between endogenous thymidine concentrations and [18F] FLT uptake in a range of preclinical tumour models K Heinzmann, DJ Honess, DY Lewis, DM Smith, C Cawthorne, H Keen, ... EJNMMI research 6 (1), 63, 2016 | 13 | 2016 |
| Response Monitoring with [18F] FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases S Heskamp, L Heijmen, D Gerrits, JDM Molkenboer-Kuenen, ... Molecular Imaging and Biology 19 (4), 540-549, 2017 | 11 | 2017 |
| Thymidine Metabolism as Confounding Factor of 3’-Deoxy-3’-[18F] Fluorothymidine Uptake after Therapy in a Colorectal Cancer Model S Schelhaas, L Wachsmuth, S Hermann, N Rieder, A Heller, ... Journal of Nuclear Medicine, jnumed. 117.206250, 2018 | 7 | 2018 |
| 3′-Deoxy-3′-[18F] Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models S Schelhaas, K Heinzmann, DJ Honess, DM Smith, H Keen, S Heskamp, ... Molecular Imaging and Biology, 1-6, 2017 | 6 | 2017 |
| The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and demonstrates a mechanism of action distinct … TA Yap, MI Walton, KM Grimshaw, RH te Poele, PD Eve, MR Valenti, ... Cancer Research 72 (8 Supplement), 928-928, 2012 | 1 | 2012 |
| Correction to: The relationship between endogenous thymidine concentrations and [18F] FLT uptake in a range of preclinical tumour models K Heinzmann, DJ Honess, DY Lewis, DM Smith, C Cawthorne, H Keen, ... EJNMMI research 7, 2017 | | 2017 |
| Investigating the effects or AKT/PKB inhibitors on [18F]-FDG uptake in cancer cells K Heinzmann Institute of Cancer Research (University Of London), 2012 | | 2012 |
| The relationship between endogenous thymidine concentrations and [18F] FLT uptake 2 K Heinzmann, DJ Honess, DY Lewis, DM Smith EJNMMI Research 1, 0 | | |
